Efficacy and Safety of Sofosbuvir/Velpatasvir ± Ribavirin for 12 Weeks in Adults With Chronic HCV Infection and Decompensated Cirrhosis

NCT02996682 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

102

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C Virus Infection

Interventions

DRUG: SOF/VEL
DRUG: RBV

Sponsor

Gilead Sciences